BR112023022921A2 - Fabricação de agentes de contraste diméricos - Google Patents
Fabricação de agentes de contraste diméricosInfo
- Publication number
- BR112023022921A2 BR112023022921A2 BR112023022921A BR112023022921A BR112023022921A2 BR 112023022921 A2 BR112023022921 A2 BR 112023022921A2 BR 112023022921 A BR112023022921 A BR 112023022921A BR 112023022921 A BR112023022921 A BR 112023022921A BR 112023022921 A2 BR112023022921 A2 BR 112023022921A2
- Authority
- BR
- Brazil
- Prior art keywords
- contrast agents
- manufacture
- dimmer
- gadolinium
- dimeric contrast
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/122—Macromolecular compounds dimers of complexes or complex-forming compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21187883 | 2021-07-27 | ||
| PCT/EP2022/070901 WO2023006721A1 (en) | 2021-07-27 | 2022-07-26 | Manufacturing of dimeric contrast agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023022921A2 true BR112023022921A2 (pt) | 2024-02-27 |
Family
ID=77367218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023022921A BR112023022921A2 (pt) | 2021-07-27 | 2022-07-26 | Fabricação de agentes de contraste diméricos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12290576B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4377323B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7774081B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240034693A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117412980A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022317221A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023022921A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3216972A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3041651T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308888A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014582A (cg-RX-API-DMAC7.html) |
| PL (1) | PL4377323T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023006721A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2991736T3 (es) * | 2020-07-27 | 2024-12-04 | Bracco Imaging Spa | Fabricación de agentes de contraste diméricos |
| AU2022318032A1 (en) * | 2021-07-27 | 2023-12-21 | Bracco Imaging Spa | Process for the manufacturing of a gadolinium complex solution |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4009119A1 (de) * | 1990-03-19 | 1991-09-26 | Schering Ag | 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
| DE4035760A1 (de) * | 1990-11-08 | 1992-05-14 | Schering Ag | Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
| IT1291624B1 (it) * | 1997-04-18 | 1999-01-11 | Bracco Spa | Chelati complessi di metalli paramagnetici a bassa tossicita' |
| DE19849465A1 (de) | 1998-10-21 | 2000-04-27 | Schering Ag | Dimere Ionenpaare, Verfahren zu ihrer Herstellung und ihre Verwendung als Kontrastmittel |
| IT1304501B1 (it) * | 1998-12-23 | 2001-03-19 | Bracco Spa | Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza |
| PL3753929T3 (pl) | 2015-12-10 | 2023-03-13 | Bracco Imaging Spa | Dimeryczne środki kontrastowe |
| IL293806B1 (en) * | 2019-12-13 | 2026-05-01 | Bracco Imaging Spa | Production of protected DO3A salts |
-
2022
- 2022-07-26 MX MX2023014582A patent/MX2023014582A/es unknown
- 2022-07-26 WO PCT/EP2022/070901 patent/WO2023006721A1/en not_active Ceased
- 2022-07-26 AU AU2022317221A patent/AU2022317221A1/en active Pending
- 2022-07-26 BR BR112023022921A patent/BR112023022921A2/pt unknown
- 2022-07-26 IL IL308888A patent/IL308888A/en unknown
- 2022-07-26 US US18/565,770 patent/US12290576B2/en active Active
- 2022-07-26 EP EP22754878.1A patent/EP4377323B1/en active Active
- 2022-07-26 CN CN202280039128.1A patent/CN117412980A/zh active Pending
- 2022-07-26 KR KR1020237042178A patent/KR20240034693A/ko active Pending
- 2022-07-26 JP JP2023577348A patent/JP7774081B2/ja active Active
- 2022-07-26 ES ES22754878T patent/ES3041651T3/es active Active
- 2022-07-26 PL PL22754878.1T patent/PL4377323T3/pl unknown
- 2022-07-26 CA CA3216972A patent/CA3216972A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4377323A1 (en) | 2024-06-05 |
| CN117412980A (zh) | 2024-01-16 |
| AU2022317221A1 (en) | 2023-11-16 |
| IL308888A (en) | 2024-01-01 |
| CA3216972A1 (en) | 2023-02-02 |
| PL4377323T3 (pl) | 2025-12-01 |
| EP4377323C0 (en) | 2025-07-02 |
| KR20240034693A (ko) | 2024-03-14 |
| ES3041651T3 (en) | 2025-11-13 |
| US12290576B2 (en) | 2025-05-06 |
| MX2023014582A (es) | 2023-12-13 |
| WO2023006721A1 (en) | 2023-02-02 |
| US20240269330A1 (en) | 2024-08-15 |
| JP7774081B2 (ja) | 2025-11-20 |
| JP2024527691A (ja) | 2024-07-26 |
| EP4377323B1 (en) | 2025-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Emin et al. | Small soluble α-synuclein aggregates are the toxic species in Parkinson’s disease | |
| BR112023000078A2 (pt) | Fabricação de agentes de contraste diméricos | |
| Li et al. | Quercetin prevents primordial follicle loss via suppression of PI3K/Akt/Foxo3a pathway activation in cyclophosphamide-treated mice | |
| Ratto et al. | Direct control of lysosomal catabolic activity by mTORC1 through regulation of V-ATPase assembly | |
| Puri et al. | A DNM2 centronuclear myopathy mutation reveals a link between recycling endosome scission and autophagy | |
| Algamal et al. | Atomic-resolution map of the interactions between an amyloid inhibitor protein and amyloid β (Aβ) peptides in the monomer and protofibril states | |
| EP1366710A4 (en) | PARALLEL MR TOMOGRAPHY WITH HIGH PRECISION COIL SENSITIVITY MAP | |
| BRPI0508036A (pt) | derivados fundidos de pirazola | |
| Grandal et al. | Differential Roles of Grb 2 and AP‐2 in p38 MAPK‐and EGF‐Induced EGFR Internalization | |
| ATE433331T1 (de) | Kontrastmittel für die magnetresonanztomographie und entsprechende verfahren | |
| Yanase et al. | Immunoreactivities for hepcidin, ferroportin, and hephaestin in astrocytes and choroid plexus epithelium of human brains | |
| MX2023014582A (es) | Fabricacion de agentes de contraste dimericos. | |
| Sheftic et al. | Inhibition of semen-derived enhancer of virus infection (SEVI) fibrillogenesis by zinc and copper | |
| Araújo et al. | Early calpain‐mediated proteolysis following AMPA receptor activation compromises neuronal survival in cultured hippocampal neurons | |
| Bernadzki et al. | Liprin-α-1 is a novel component of the murine neuromuscular junction and is involved in the organization of the postsynaptic machinery | |
| Fujibuchi et al. | Expression and phosphorylation of TOPK during spermatogenesis | |
| Hobdy‐Henderson et al. | Dynamics of the apical plasma membrane recycling system during cell division | |
| Wilson et al. | The p53 homologue p73 accumulates in the nucleus and localizes to neurites and neurofibrillary tangles in Alzheimer disease brain | |
| WO2006099516A3 (en) | Methods for magnetic resonance imaging | |
| Yang et al. | Gedunin Degrades Aggregates of Mutant Huntingtin Protein and Intranuclear Inclusions via the Proteasomal Pathway in Neurons and Fibroblasts from Patients with Huntington’s Disease: W. Yang et al.: Gedunin Enhances Mutant Huntingtin Protein Degradation | |
| Chen et al. | Identification and characterization of PEBP as a calpain substrate | |
| Vervliet et al. | Inactive ryanodine receptors sustain lysosomal availability for autophagy by promoting ER-lysosomal contact site formation | |
| Szivak et al. | Subcellular localization and structural function of endogenous phosphorylated phosphatidylinositol 4-kinase (PI4K92) | |
| Fulle et al. | Nerve growth factor inhibits apoptosis induced by S-100 binding in neuronal PC12 cells | |
| Xiao et al. | NADPH-oxidase 2 promotes autophagy in spinal neurons during the development of morphine tolerance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |